Q2 2022 EPS Estimates for Charles River Laboratories International, Inc. (NYSE:CRL) Increased by Analyst

Charles River Laboratories International, Inc. (NYSE:CRL) – KeyCorp lifted their Q2 2022 EPS estimates for shares of Charles River Laboratories International in a research note issued on Tuesday, January 11th. KeyCorp analyst D. Hooker now forecasts that the medical research company will post earnings of $2.89 per share for the quarter, up from their prior estimate of $2.85. KeyCorp also issued estimates for Charles River Laboratories International’s Q3 2022 earnings at $2.98 EPS, Q4 2022 earnings at $3.06 EPS, FY2022 earnings at $11.67 EPS and FY2023 earnings at $13.53 EPS.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Tuesday, November 2nd. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.58 by $0.12. Charles River Laboratories International had a return on equity of 23.14% and a net margin of 11.58%. The company had revenue of $895.90 million during the quarter, compared to analyst estimates of $902.03 million. During the same quarter last year, the company earned $2.33 earnings per share. The firm’s quarterly revenue was up 20.5% on a year-over-year basis.

A number of other analysts have also recently commented on CRL. Deutsche Bank Aktiengesellschaft boosted their price target on Charles River Laboratories International from $354.00 to $409.00 and gave the stock a “buy” rating in a research report on Tuesday, November 16th. Evercore ISI reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research report on Thursday, October 14th. Morgan Stanley cut their price objective on shares of Charles River Laboratories International from $480.00 to $465.00 and set an “overweight” rating for the company in a research report on Thursday, November 4th. Citigroup dropped their target price on shares of Charles River Laboratories International from $425.00 to $400.00 and set a “neutral” rating for the company in a report on Thursday, November 4th. Finally, Robert W. Baird reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Monday, December 20th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Buy” and an average price target of $415.50.

CRL opened at $355.01 on Thursday. The company has a current ratio of 1.40, a quick ratio of 1.22 and a debt-to-equity ratio of 1.19. The company has a market cap of $17.92 billion, a P/E ratio of 45.87, a P/E/G ratio of 2.20 and a beta of 1.17. Charles River Laboratories International has a 12 month low of $249.48 and a 12 month high of $460.21. The business’s 50-day moving average price is $366.58 and its 200-day moving average price is $397.38.

Several institutional investors and hedge funds have recently made changes to their positions in the company. AdvisorNet Financial Inc acquired a new stake in shares of Charles River Laboratories International in the third quarter worth approximately $26,000. Assetmark Inc. raised its stake in shares of Charles River Laboratories International by 644.4% during the second quarter. Assetmark Inc. now owns 67 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 58 shares during the period. Jones Financial Companies Lllp raised its stake in shares of Charles River Laboratories International by 200.0% during the third quarter. Jones Financial Companies Lllp now owns 75 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 50 shares during the period. Clearstead Advisors LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter worth approximately $32,000. Finally, Wolff Wiese Magana LLC grew its position in shares of Charles River Laboratories International by 119.1% during the third quarter. Wolff Wiese Magana LLC now owns 103 shares of the medical research company’s stock worth $42,000 after buying an additional 56 shares in the last quarter. Institutional investors and hedge funds own 91.64% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support.

See Also: How liquidity affects the bid-ask spread

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.